2. UroToday Home
  3. Video Lectures

ASCO 2021 Videos

Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio
November 2, 2021
Details
Single Priming Dose of 177Lu-PSMA-617 Followed by Pembrolizumab in mCRPC in a Phase 1b Trial - Rahul Aggarwal
August 27, 2021
Details
Impact of Age on Castration Rates from The HERO Study – Michael Cookson
August 27, 2021
Details
Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas
August 27, 2021
Details
42-Month Follow-up of KEYNOTE-426, Pembrolizumab plus Axitinib First-Line Treatment for Advanced Renal Cell Carcinoma - Thomas Powles
August 18, 2021
Details
Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris
August 13, 2021
Details
Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor
August 12, 2021
Details
Validating the Genomic Classifier to Identify Patients With a High Risk of Metastasis Among African American Men With Early Localized Prostate Cancer, VANDAAM Study – Kosj Yamoah
August 4, 2021
Details
Genomic Analysis and Assessment of Treatment Patterns To Better Understand Disparities in Advanced Prostate Cancer – Brandon Mahal
July 30, 2021
Details
Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt
July 29, 2021
Details
COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC, The COMBAT Study - Mark Markowski
July 29, 2021
Details
Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander
July 29, 2021
Details
Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi
July 21, 2021
Details
VEGF Blockade and Combination Therapeutic Options in Advanced Renal Cell Carcinoma - Andrea Apolo
July 8, 2021
Details
Differences in the Pattern of and the Response to Treatment Not Just Race - Elisabeth Heath
June 27, 2021
Details
Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath
June 27, 2021
Details
The Addition of TAK-700 to Testosterone Suppression, Its Effect on Survival in mCSPC SWOG 1216 – Neeraj Agarwal
June 22, 2021
Details
Case-Based Discussions Illuminate the Complexities of Oligometastatic Prostate Cancer Treatment - Phuoc Tran
June 21, 2021
Details
The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen
June 21, 2021
Details
The State of CRPC Treatment in Spain: Expert Opinions on Enzalutamide and Abiraterone - Elena Castro & Fernando Lopez-Campos
June 18, 2021
Details
Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra
June 17, 2021
Details
Impact of Age on Efficacy and Safety of Relugolix in the Phase 3 HERO Study Versus Leuprolide in Men with Advanced Prostate Cancer - Fred Saad
June 16, 2021
Details
Updated Interim Efficacy and Safety Results from a Phase I/IIa Trial HPN424 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Tomasz Beer
June 16, 2021
Details
Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer - Andrea Necchi
June 13, 2021
Details
HCRN GU 16-257 a Phase 2 Trial of Gemcitabine, Cisplatin, Plus Nivolumab Shows Promise for Bladder-Sparing in Muscle- Invasive Bladder Cancer (MIBC)- Matthew Galsky
June 13, 2021
Details
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar
June 10, 2021
Details
Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor
June 10, 2021
Details
Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark Fleming
June 9, 2021
Details
Time to End of Next-Line Therapy in the JAVELIN Bladder 100 - Petros Grivas
June 9, 2021
Details
Cisplatin and Gemcitabine With or Without Berzosertib in Patients with Advanced Urothelial Carcinoma - Tian Zhang
June 9, 2021
Details
Longer-Term Outcomes of Patients with Testicular Cancer: Late Relapses and Toxicities - Sia Daneshmand
June 9, 2021
Details
The Effect of Mandated Bone Protective Agents on Fracture Risk With Longer Follow-Up (EORTC 1333 / PEACE III Trial) – Fred Saad
June 8, 2021
Details
Long-Term Follow-Up From the KEYNOTE-052 Trial, Pembrolizumab in the First-Line Setting in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer – Arjun Balar
June 8, 2021
Details
Feladilimab Alone and in Combination with Pembrolizumab In Previously-Treated Urothelial Carcinoma Patients, An expansion Cohort of the INDUCE-1 Trial - Arjun Balar
June 8, 2021
Details
First Results of PEACE-1 A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone and/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer mCSPC - Karim Fizazi
June 8, 2021
Details
Examining the Role of Docetaxel with Radiation Therapy and ADT in Non-Metastatic Prostate Cancer - Anthony D'Amico & Philip Kantoff
June 7, 2021
Details
The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor
June 7, 2021
Details
KEYNOTE-564 Demonstrates Improvement in Disease-Free Survival - A New Standard of Care for High-Risk Kidney Cancer - Rana McKay
June 6, 2021
Details
177Lu-PSMA-617 Significantly Improves Overall Survival and Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer in VISION study - Mary-Ellen Taplin
June 6, 2021
Details
177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris
June 6, 2021
Details
Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - Scott Tagawa
June 5, 2021
Details
Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas
June 5, 2021
Details
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar
June 4, 2021
Details
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi
June 4, 2021
Details
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland
June 4, 2021
Details
Apalutamide Improves Overall Survival and rPFS While Preserving Health-Related Quality of Life in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Neeraj Agarwal
June 3, 2021
Details